View Older Stories View More Recent Stories

May 13, 2020 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
May 13, 2020 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Ne
May 13, 2020 05:00PM New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC
May 13, 2020 05:54AM Merck (MRK) Animal Health Reports Acquires U.S. Rights to SENTINEL Brand of Combination Parasiticides for Companion Animals
May 13, 2020 02:00AM Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
May 13, 2020 01:38AM Virbac to divest U.S. Rights to SENTINEL® brands to MSD Animal Health
May 11, 2020 09:00AM MilliporeSigma Granted U.S. Patents for Foundational CRISPR-Cas9 Technology
May 8, 2020 05:25PM LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
May 8, 2020 06:45AM Merck Announces Virtual 2020 Annual Shareholders Meeting
May 7, 2020 06:55AM Merck to Present at the BofA Securities 2020 Health Care Conference
May 7, 2020 06:45AM Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
May 6, 2020 06:47AM Merck (MRK) Announces Results of Phase 3 Trial Evaluating RECARBRIO Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available
May 6, 2020 06:45AM Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Ava
May 5, 2020 06:45AM Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
Apr 28, 2020 05:08PM Merck (MRK) Announces FDA Approves KEYTRUDA for Use at Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Apr 28, 2020 04:35PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Apr 28, 2020 06:45AM Merck Announces First-Quarter 2020 Financial Results
Apr 27, 2020 06:57AM Merck (MRK) Announces First Clinical Outcomes Evaluating Six-Week Dosing Schedule for KEYTRUDA Presented at AACR
Apr 27, 2020 06:55AM First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
Apr 27, 2020 06:46AM Merck (MRK), Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
Apr 27, 2020 06:45AM Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
Apr 24, 2020 06:56AM Merck (MRK) Announces LYNPARZA Demonstrated OS Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Apr 24, 2020 06:55AM LYNPARZA® (Olaparib) Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Apr 24, 2020 06:55AM LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Apr 23, 2020 06:49AM Merck (MRK) Resubmits sBLAs for KEYTRUDA Six-Week Dosing Schedule
Apr 23, 2020 06:45AM Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Apr 21, 2020 06:45AM Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts
Apr 15, 2020 06:50AM Merck (MRK) Reports US Launch of ONTRUZANT (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab)
Apr 15, 2020 06:45AM Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab)
Apr 13, 2020 06:57AM AstraZeneca (AZN), Merck (MRK) Announce KOSELUGO Approved by FDA for Pediatric Patients Two Years and Older With NF1 and Symptomatic, Inoperable PN
Apr 13, 2020 06:55AM KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
Apr 9, 2020 08:00AM Merck Announces $3M Commitment to Address Critical Maternal Health Needs During COVID-19 Pandemic
Apr 9, 2020 06:13AM Pfizer (PFE), EMD Serono Granted FDA Breakthrough Therapy Designation & Submit Application for BAVENCIO
Apr 9, 2020 06:00AM EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Apr 7, 2020 08:00AM MilliporeSigma Awarded Second U.S. Patent for CRISPR Gene-Editing Technology
Apr 7, 2020 06:45AM Merck (MRK) Receives Priority Review from FDA for Second Application for KEYTRUDA Based on Biomarker
Apr 7, 2020 06:45AM Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type
Apr 2, 2020 06:46AM Merck (MRK) Announces KEYTRUDA Significantly Improved PFS as First-Line Treatment for MSI-H or dMMR Colorectal Cancer
Apr 2, 2020 06:45AM Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (d
Apr 2, 2020 06:30AM Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28
Apr 1, 2020 04:00PM Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Apr 1, 2020 04:00PM Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Mar 30, 2020 06:11AM Merck (MRK) Reports Investigational Drug Vericiguat Significantly Reduced the Risk of Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death
Mar 28, 2020 10:00AM Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with A
Mar 25, 2020 05:00PM Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
Mar 22, 2020 11:52AM Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City
Mar 20, 2020 05:01PM Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
Mar 17, 2020 06:46AM Merck (MRK) Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant
Mar 17, 2020 06:45AM Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
Mar 13, 2020 08:00AM EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
View More Recent Stories View Older Stories